Introduction: The Cilotax stent®, cilostazol and paclitaxel dual-coating stent (CPD-stent), was created for synergy effect to increase the anti-proliferative effect of paclitaxel and the anti-thrombotic effect of cilostazol. There were no published data regarding the clinical efficacy and safety of CPD-stents compared with 1st generation (sirolimus-eluting stent, SES and paclitaxel-eluting stent, PES) and 2nd generation (zotarolimus-eluting stent, ZES and everolimus-eluting stent, EES and zotarolimus-eluting stent with biolinx polymer, ZES-BP) drug-eluting stents(DES) following primary percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI).
Hypothesis: We evaluated the one-year outcome of CPD-stents vs 5 types DES (ZES-BP, EES, ZES, SES and PES ) for the primary PCI.
Methods: A prospective, open-labeled, single-center cohort has been performed at Gil hospital Gachon university in Korea. All patients will be clinically followed-up for 12 months. The primary endpoint was major adverse cardiac event (MACE): the composite of cardiac death (CD), recurrent myocardial infarction (MI) and ischemia-driven target lesion revascularization (TLR) at 12 months. Stent thromboses (ST) by ARC definition were analyzed.
Results: Total 1,173 patients (CPD-S=198, ZES-BP=178, EES=197, ZES=203, SES=203, PES=194) who were completed more than 1 year were analyzed. 1 year MACE were 3.0%, 3.4%, 2.0%, 5.9%, 3.4% and 5.7% in CPD-S, ZES-BP, EES, ZES, SES and PES group (p=ns). Cardiac death were 1.0%, 2.3%, 1.0%, 2.5%, 1.5% and 1.0% , respectively (p=ns). ST were 2.5%, 0%, 0%, 2.0%, 2.0% and 2.0% (p=ns).
Conclusions: Campared with 1st and 2nd generation DES (SES, PES, ZES, EES and ZES-BP), CPD-stents showed similar one-year clinical outcomes in terms of MACE in patients with STEMI following primary PCI.